Clear Search

Showing 15 results for “Petri M”.

December 2023
November 2023

EULAR Recommendations for the Management of Systemic Lupus Erythematosus: 2023 Update

Ann Rheum Dis 2023;83(1):15–29 DOI: 10.1136/ard-2023-224762

 The objective of this international task force was to update the EULAR recommendations for the management of SLE. The Task Force agreed on 5 overarching principles and 13 recommendations, generating an overall framework for the approach to a patient with SLE. The updated recommendations provide consensus guidance on the management of SLE, combining evidence and expert opinion.

more…

May 2023

Belimumab Versus Anifrolumab in Adults with Systemic Lupus Erythematosus: An Indirect Comparison of Clinical Response at 52 Weeks

Lupus Sci. Med 2023;10:e000907 doi 10.1136/lupus-2023-000907

This retrospective study by Neupane, et al. compared belimumab and anifrolumab efficacy at 52 weeks in SLE patients. It concluded that belimumab and anifrolumab have equal efficacy, but further studies would be needed for specific patient demographics.

more…

March 2023
February 2023
November 2022

Belimumab Use During Pregnancy: Interim Results of the Belimumab Pregnancy Registry

Birth Defects Res. 2022. Epub ahead of print doi: 10.1002/bdr2.2091

There was no pattern or common mechanism of birth defects associated with belimumab within the Belimumab Pregnancy Registry (BPR) data.

more…

September 2022

Trajectory of Damage Accrual in Systemic Lupus Erythematosus based on Ethnicity and Socioeconomic Factors

J Rheumatol. 2022. Epub ahead of print doi: 10.3899/jrheum.211135

Large study confirms that cumulative damage accrual is faster in African-Americans, compared to Caucasians, highlighting that ethnicity plays the major role in damage accrual, regardless of socioeconomic status.

more…